



(51) International Patent Classification:

C12N 5/10 (2006.01) A61K 35/17 (2015.01)
C07K 14/275 (2006.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/SG2024/050384

(22) International Filing Date:

07 June 2024 (07.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202301606S 07 June 2023 (07.06.2023) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: WANG, Cheng-I; 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). LEE, Wen-Hsin; 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). WANG, Bei; 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). YEAP, Yee Chin, Yvonne; 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). NGOH, Zi Xian Eve; 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG).

(74) Agent: TECK YEOW, Lim; Donaldson & Burkinshaw LLP, P.O. Box 3667 Robinson Road Post Office, Singapore 905667 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: HER2 CHIMERIC ANTIGEN RECEPTOR SECRETING




Figure 1A

(57) Abstract: There is provided a modified cell expressing (a) a chimeric antigen receptor targeting HER2, and (b) a multi-specific antigen binding protein, variant or binding fragment thereof that binds one or more target, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule) and a second antigen binding protein, variant or binding fragment thereof that binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof that binds to EpCAM comprises a heavy chain variable region and/or a light chain variable region comprise sequences as disclosed herein. Also disclosed are methods of producing/generating the cell as disclosed herein and methods of treatment employing the cell as disclosed herein.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))